Retention of HIV-Infected Children on Antiretroviral Treatment in HIV Care and Treatment Programs in Kenya, Mozambique, Rwanda, and Tanzania

被引:51
|
作者
McNairy, Margaret L. [1 ,2 ]
Lamb, Matthew R. [1 ]
Carter, Rosalind J. [1 ]
Fayorsey, Ruby [1 ]
Tene, Gilbert [3 ]
Mutabazi, Vincent [4 ,5 ]
Gusmao, Eduarda [6 ]
Panya, Millembe [7 ]
Sheriff, Mushin [8 ]
Abrams, Elaine J. [9 ]
机构
[1] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY 10031 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Columbia Univ, Mailman Sch Publ Hlth, ICAP, Kigali, Rwanda
[4] Rwanda Biomed Ctr, Kigali, Rwanda
[5] Rwanda Minist Hlth, Kigali, Rwanda
[6] Columbia Univ, Mailman Sch Publ Hlth, ICAP, Maputo, Mozambique
[7] Columbia Univ, Mailman Sch Publ Hlth, ICAP, Dar Es Salaam, Tanzania
[8] Columbia Univ, Mailman Sch Publ Hlth, ICAP, Mombasa, Kenya
[9] Columbia Univ, Coll Phys & Surg, New York, NY USA
关键词
HIV; retention; pediatric; antiretrovirals; FOLLOW-UP; HIV-1-INFECTED CHILDREN; CLINICAL-OUTCOMES; EXPOSED CHILDREN; EARLY MORTALITY; COTE-DIVOIRE; THERAPY; TRANSMISSION; PREDICTORS; SURVIVAL;
D O I
10.1097/QAI.0b013e318278bcb0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Retention of children in HIV care is essential for prevention of disease progression and mortality. Methods: Retrospective cohort of children (aged 0 to <15 years) initiating antiretroviral treatment (ART) at health facilities in Kenya, Mozambique, Rwanda, and Tanzania, from January 2005 to June 2011. Retention was defined as the proportion of children known to be alive and attending care at their initiation facility; lost to follow-up (LTF) was defined as no clinic visit for more than 6 months. Cumulative incidence of ascertained survival and retention after ART initiation was estimated through 24 months using Kaplan-Meier methods. Factors associated with LTF and death were assessed using Cox proportional hazard modeling. Results: A total of 17,712 children initiated ART at 192 facilities: median age was 4.6 years [interquartile ratio (IQR), 1.9-8.3], median CD4 percent was 15% (IQR, 10-20) for children younger than 5 years and 265 cells per microliter (IQR, 111-461) for children aged 5 years or older. At 12 and 24 months, 80% and 72% of children were retained with 16% and 22% LTF and 5% and 7% known deaths, respectively. Retention ranged from 71% to 95% at 12 months and from 62% to 93% at 24 months across countries, respectively, and was lowest for children younger than 1 year (51% at 24 months). LTF and death were highest in children younger than 1 year and children with advanced disease. Conclusions: Retention was lowest in young children and differed across country programs. Young children and those with advanced disease are at highest risk for LTF and death. Further evaluation of patient-and program-level factors is needed to improve health outcomes.
引用
收藏
页码:E70 / E81
页数:12
相关论文
共 50 条
  • [31] IMPACT OF ANTIRETROVIRAL TREATMENT ON SEXUAL FUNCTION OF HIV-INFECTED WOMEN
    Zallio, Veronica
    Marconi, Luis
    Parenti, Pablo
    Agostini, Marcela
    Lupo, Sergio
    REVISTA MEDICA DE ROSARIO, 2015, 81 (01): : 19 - 23
  • [32] Place of antiretroviral drugs in the treatment of HIV-infected people in Africa
    Agid, F
    Ahouanto, M
    Ariyoshi, K
    Badiane, S
    Bakaramfitiye, D
    Benga, E
    Bonnet, D
    Bouchaud, O
    Canon, C
    Carosi, G
    Chièze, F
    Colebunders, B
    Coll-Seck, AM
    Corrah, T
    Coulaud, JP
    Coulibaly, IM
    Courpotin, C
    Dabis, F
    De Cock, K
    Delaporte, E
    Desclaux, A
    Diadhiou, F
    Diakhate, L
    Diallo, S
    Diouf, G
    Dozon, JP
    Fall, M
    Fassin, D
    Floury, B
    Gomez, VF
    Gruénais, ME
    Grunitzki-Békéle, M
    Gueye, M
    Hane, A
    Himmich, H
    Kabou, F
    Kadio, A
    Katabira, E
    Landman, R
    Larouzé, B
    Lawson, A
    Lévy, JP
    Maiga, Y
    Malkin, JE
    Marchal, C
    Marlink, R
    Martelli, A
    Matheron, S
    Mboup, S
    Méda, N
    AIDS, 1999, 13 (02) : IAS1 - IAS3
  • [33] Antiretroviral treatment regimen outcomes among HIV-infected prisoners
    Springer, Sandra A.
    Friedland, Gerald H.
    Doros, Gheorghe
    Pesanti, Edward
    Altice, Frederick L.
    HIV CLINICAL TRIALS, 2007, 8 (04): : 205 - 212
  • [34] Knowledge of Antiretroviral Treatment and Associated Factors in HIV-Infected Patients
    Nguyen, Lam Van
    Nguyen, Thao N. P.
    Thach, Anh N.
    Lam, Anh N.
    Lam, Duc Q.
    Duong, Chu X.
    Pham, Suol T.
    Nguyen, Thao H.
    Perwitasari, Dyah A.
    Taxis, Katja
    Nguyen, Phuong M.
    Nguyen, Thang
    HEALTHCARE, 2021, 9 (04)
  • [35] CARE-SEEKING BEHAVIOURS AMONG HIV-INFECTED ADULTS IN MOZAMBIQUE: BARRIERS AND FACILITATORS TO TIMELY ENROLLMENT IN HIV CARE AND TREATMENT
    Magaco, Amilcar
    SEXUALLY TRANSMITTED INFECTIONS, 2017, 93 : A235 - A235
  • [36] When and how to start antiretroviral treatment in HIV-infected adults?
    Hoen, B.
    JOURNAL DES ANTI-INFECTIEUX, 2011, 13 (02) : 117 - 121
  • [37] Treatment of heavily antiretroviral-experienced HIV-infected patients
    Van Lunzen, Jan
    AIDS REVIEWS, 2007, 9 (04) : 246 - 253
  • [38] Viral loads in HIV-infected adolescents on antiretroviral treatment.
    Arlievsky, N
    Purtill, F
    Frawley, L
    Li, KM
    Munoz, JL
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 269 - 269
  • [39] Clinical trials of antiretroviral treatment interruption in HIV-infected individuals
    Lau, Jillian S. Y.
    Smith, Miranda Z.
    Lewin, Sharon R.
    McMahon, James H.
    AIDS, 2019, 33 (05) : 773 - 791
  • [40] Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An update
    Cressey, Tim R.
    Lallemant, Marc
    INFECTION GENETICS AND EVOLUTION, 2007, 7 (02) : 333 - 342